JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

PSMA-Directed Theranostics in Prostate Cancer

  • 0NYMC-Landmark Medical Center, Woonsocket, RI 02895, USA.
Biomedicines +

|

August 28, 2025

|

August 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Prostate cancer treatments are advancing with prostate cancer-specific membrane antigen (PSMA) targeting. PSMA-based PET imaging and therapeutics offer improved detection and management for advanced prostate cancer.

Area Of Science

  • Oncology
  • Radiochemistry
  • Immunotherapy

Background

  • Prostate cancer is a leading cause of cancer death in men, with high-risk cases often becoming resistant to standard treatments.
  • Prostate cancer-specific membrane antigen (PSMA) is overexpressed in prostate cancer and linked to poorer survival.
  • Current diagnostic methods for staging and treatment selection have limitations.

Purpose Of The Study

  • To review the emerging field of PSMA-based theranostics for prostate cancer.
  • To highlight advancements in PSMA-targeted diagnostics and therapeutics.
  • To discuss the integration of PSMA theranostics into clinical practice.

Main Methods

  • Review of recent clinical trials and scientific literature on PSMA-based PET radiopharmaceuticals.
  • Analysis of PSMA-targeted therapeutic strategies including radioligands, CAR-T, BiTEs, and ADCs.
  • Discussion of PSMA expression as a biomarker for risk stratification and treatment response.

Main Results

  • PSMA-based PET imaging demonstrates superior sensitivity and specificity compared to traditional methods for detecting prostate cancer lesions.
  • Several PSMA-targeted therapies are under development, showing promise in clinical trials.
  • Increased PSMA expression is a validated independent risk factor for adverse outcomes in prostate cancer.

Conclusions

  • PSMA-based theranostics represent a significant advancement in prostate cancer management.
  • These approaches are increasingly being integrated into standard care protocols for improved patient outcomes.
  • Targeting PSMA offers a promising strategy for both diagnosis and treatment of advanced prostate cancer.

Keywords: